A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab
机构：[1]Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Cancer Center, Beijing, China[2]Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China[3]First Affiliated Hospital, Jilin University, Changchun, Jilin, China[4]Affiliated Hospital of Academy of Military Medical Sciences, Beijing, China[5]Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China[6]Cancer Center of Hebei Province and The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China河北医科大学第四医院外一科临床科室[7]Peking University Cancer Hospital & Institute, Beijing, China[8]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China华中科技大学同济医学院附属同济医院[9]Affiliated Cancer Hospital of Nanjing Medical University, Jiangsu Cancer Hospital and Jiangsu Institute of Cancer Research, Nanjing, Jiangsu, China[10]Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China[11]Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China[12]Jiangsu Hengrui Medicine Co., Ltd., Shanghai, China
第一作者机构：[1]Cancer Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, National Cancer Center, Beijing, China
推荐引用方式(GB/T 7714)：
Xu Binghe,Liu Yunjiang.A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[J].CANCER RESEARCH.2018,78(4):
APA：
Xu, Binghe&Liu, Yunjiang.(2018).A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab.CANCER RESEARCH,78,(4)
MLA：
Xu, Binghe,et al."A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab".CANCER RESEARCH 78..4(2018)
医学